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Background: The majority of patients with intrahepatic cholangiocarcinoma (IHCC) who undergo complete tumor
resection subsequently develop tumor recurrence. The objectives of this study were to determine the risk factors
for IHCC recurrence after curative (R0) liver resection and to identify the feasibility about postoperative adjuvant
radiation therapy (RT).
Methods: We retrospectively reviewed patients who underwent liver resection for IHCC between April 1995
and December 2012 at Samsung Medical Center. Cox regression analysis was performed to determine risk
factors of recurrence. Patients with a recurrence in remnant liver within 2 cm from the resection margin, with
or without locoregional lymph node (LN) metastases, were considered as potential RT candidates. Center-of-mass
(COM) distances between the recurrent cancers and the cut surface were measured with MATLAB.
Results: We included 153 out of 198 patients who underwent partial liver resection for IHCC. About two thirds (n = 93,
60.8 %) of patients developed recurrent disease. The median recurrence-free survival (RFS) was 14 months (range,
0–204). Tumor size ≥4.0 cm, LN metastasis and multiple tumors were significant predictors of IHCC recurrence on
multivariate analysis. Tumor size ≥5.0 cm was the only factor associated with recurrence beyond the RT field in patients
with recurrence. Among 93 patients with recurrence, 16 (17.2 %) patients were recurred in the RT field.
Conclusion: After curative resection in IHCC, more than 60 % of patients recurred, and among recurred
patients, 17.2 % were recurred within the RT field. Consequently, for control of locoregional recurrence,
adjuvant RT could be carefully considered in patients with recurrence factors. Especially, patients with a tumor
size larger than 5 cm should be judiciously selected for adjuvant RT.
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in any medium, provided the original work is
(http://creativecommons.org/publicdomain/zero[1, 2]. Although hilar CC remains the most common
type, the incidence of intrahepatic cholangiocarcinoma
(IHCC) is rising [3–5], and IHCC currently accounts for
20 % of all CC [5].
IHCC has a dismal prognosis with limited treatment
options and a very high rate of recurrent or metastatic
disease [1, 2]. Indeed, the overall mortality rate in IHCC
approaches its incidence [6]. Currently, surgical resec-
tion offers the only chance for cure. However, as the dis-
ease lacks symptoms until late in its course, the majority
of IHCC patients have unresectable tumors at diagnosis,
and less than 50 % of patients with IHCC are surgicaldistributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction
properly credited. The Creative Commons Public Domain Dedication waiver
/1.0/) applies to the data made available in this article, unless otherwise stated.
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recurrence rates approach 52 %, with 5-year post-
resection survival rates ranging from 8 to 44 %, indi-
cating that resection alone is not sufficient for most
patients [1, 6–9, 12, 13].
Repeated surgery is limited by patients’ comorbidities
or by poor functional hepatic reserve. In patients with
recurrence, palliative treatments such as radiation and
systemic chemotherapy are the only options. However,
current studies testing the role of adjuvant chemother-
apy in IHCC are limited [14–16]. While adjuvant radi-
ation therapy may improve survival in patients with
microscopically positive margins, this remains contro-
versial [17–21] and no guidelines for adjuvant therapy
for IHCC exist [22]. The benefit of adjuvant RT in
resected IHCC will undoubtedly depend on appropri-
ate patient selection. The purpose of this study is to
identify a patient subset at high risk for locoregional
tumor recurrence after curative resection and to iden-
tify the feasibility about postoperative adjuvant radi-
ation therapy.Methods
Patient selection and data collection
We retrospectively reviewed patients 18 years of age or
older with IHCC who underwent liver resection at
Samsung Medical Center between April 1995 and
December 2012. We excluded patients with a history of
other malignancies, and those who had neoadjuvant
therapy for IHCC, M1 disease, and R2 or R1 resection.
Postoperatively, patients were followed with serial com-
puted tomography (CT) scans and serial serum tumor
marker (CA 19–9 and CEA) levels.
Pathology reports were reviewed for important prog-
nostic factors including tumor size, subtype, number
and histology, margin status, lymph node (LN) involve-
ment, and the presence of lymphovascular invasion
(LVI) and perineural invasion (PNI), which are known
important factors for tumor recurrence and patient sur-
vival [23–25]. Satellite nodules were considered as mul-
tiple tumors. Patients who did not undergo LN
dissection were regarded as node-negative, as this is
consistent with clinical practice patterns. The first post-
operative follow-up evaluation was usually 1 month after
the operation, and subsequent visits were performed ac-
cording to the surgeon’s discretion. Overall survival was
ascertained through the clinical follow-up documented
in each patient’s medical record.Recurrence classification
The regions of the recurrent cancers and the cut sur-
face were delineated on the follow-up CT or magnetic
resonance (MR) using Eclipse ver. 10.0 (Varian, PaloAlto, CA), and the structure files in digital imaging
and communications in medicine (DICOM), including
the regions, were exported to an in-house program in
MATLAB (Mathworks, Natick, NA). The closest, far-
thest, and center-of-mass (COM) distances between
the recurrent cancers and the cut surface were mea-
sured with the program. Curability was determined
according to the R-classification of the International
Union Against Cancer as R0, no residual tumor; R1,
presence of microscopic disease despite removal of all
identifiable tumor; and R2, tumor left macroscopically
in situ.
Regional LNs of IHCC included the hilar LNs. And
according to LN drainage, tumors in the right liver
(segments 5–8) included pancreaticoduodenal LNs,
and tumors in the left liver (segments 2–4) included
gastrohepatic LNs. Diseases that spread to the celiac,
periaortic, or caval LNs were usually considered dis-
tant metastases (M1 node), but clinical radiation ther-
apy (RT) fields generally encompassed periaortic or
caval LNs around celiac LNs.
Therefore, local recurrence in the present study was
defined as any recurrence within the potential plan-
ning target volume (PTV) in RT fields. We defined
the potential clinical target volume (CTV) in the
present study as remnant liver within 1 cm from re-
section margin, perihilar, periduodenal, peripancreatic,
celiac, caval, and periaortic (from 1 cm above of ce-
liac axis to left renal artery bifurcation) LN area. PTV
was decided with an additional 1 cm margin for setup
and respiration uncertainties. We assumed radiation
delivered as a 3-D conformal technique, and the
remnant liver, kidneys, stomach, duodenum, other
bowel, and spinal cord were considered as organs at
risk. Hypothetical CTV, RT fields were displayed in
Fig. 1. And, the authors hypothesized patients who
recurred in this area which is remnant liver within
2 cm of the COM with or without locoregional LN
metastasis as potential RT candidates.Statistical analysis
Summary statistics are reported as total and percent-
age for categorical variables and as median values and
range for continuous variables. Survival and recur-
rence rates were calculated by the Kaplan–Meier
method. Cox regression analysis was performed to de-
termine recurrence factors. If data for a variable were
missing in >10 % of cases, the variable was not used
in the analysis. Factors significant at a level of p < 0.1
were included in the multivariate analysis. A receiver
operating characteristics (ROC) curve was used to
identify optimal cutoff points for each marker. All
statistical analyses were carried out using IBM SPSS
Fig. 1 Hypothetical adjuvant radiotherapy fields in intrahepatic cholangiocarcinoma. Potential clinical target volume (CTV) is defined as remnant
liver within 1 cm from resection margin, perihilar, periduodenal, peripancreatic, celiac, caval, and periaortic (from 1 cm above of celiac axis to left
renal artery bifurcation) lymph node area
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considered to be statistically significant.
Results
Patients and tumor characteristics
A total of 198 patients underwent partial liver resection
for IHCC between April 1995 and December 2012. We
excluded 19 patients who had another previous malig-
nancy, four patients who had preoperative transarterial
chemoembolization (TACE), three patients who hadneoadjuvant chemotherapy before hepatectomy, a pa-
tient with bone metastasis who underwent palliative
hepatectomy, two patients with R2 disease, and 12 pa-
tients with R1 disease. Four patients were lost to follow-
up (Fig. 2).
The final study population (n = 153) had resected
IHCC only, with a median age of 59 years (range, 37–
80 years); 96 patients (62.7 %) were male. Operative and
pathologic variables are summarized in Table 1. The ma-
jority (90.1 %) of patients required a hemihepatectomy,
Fig. 2 Patient selection and recurrence after liver resection for intrahepatic cholangiocarcinoma
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Eighty-one patients (52.9 %) underwent lymphadenec-
tomy. The median tumor size of the dominant lesion
was 4.5 cm (range, 0.5–14.0 cm). LN metastasis oc-
curred in 38 patients (24.8 %), and 37 patients (24.2 %)
had multiple confirmed tumors in the final pathologic
report. One hundred seventeen patients (76.5 %) had the
mass-forming subtype of IHCC, while 36 patients
(23.5 %) had the periductal infiltrating type or combined
both types. LVI was found in 35.9 % of patients, and
perineural invasion (PNI) was found in 23.5 %. Two pa-
tients had adjuvant chemoradiation therapy after cura-
tive resection.
Recurrence and survival
After a median follow-up of 21 months (range, 1–
204 months), recurrence had developed in 93 patients
(60.8 %) (Fig. 2). Among 93 patients with recurrence, 60
patients (64.5 %) had recurrences in the remnant liver
and/or locoregional LNs. Thirty-three patients (35.5 %)
were diagnosed with distant metastasis. The most com-
mon distant metastasis site was the lung. Eleven patients
recurred in the liver, locoregional LN, and distant metasta-
sis sites. Figure 3 shows recurrence patterns of IHCC. The
median recurrence-free survival (RFS) was 14 months
(range, 0–204), and the median overall survival (OS) was
35 months (range, 1–204). Tumor size was an important
factor for recurrence based on univariate Cox regression
analysis (p < 0.001). LN metastasis, tumor subtype,
multiple tumors, LVI, PNI, and prothrombin time–
international normalized ratio (PT–INR) were recurrencefactors based on univariate analysis. The optimal cutoff for
tumor size as a recurrence risk factor was ≥4.0 cm (p <
0.001 AUC 0.740, CI 0.661–0.819). Tumor size ≥4.0 cm
(p < 0.001), LN metastasis (p = 0.006), and multiple tumors
(p = 0.015) were significant predictors of IHCC recur-
rence on multivariate analysis (Table 2). Predictors of
survival were similar to those for recurrence. On uni-
variate analysis, INR, tumor subtype, tumor size, mul-
tiple tumors, LVI, PNI, and LN metastasis were risk
factors. Tumor size ≥4.0 cm (p < 0.001), LN metastasis
(p < 0.01), multiple tumors (p = 0.014), and LVI (p =
0.015) were risk factors on multivariate analysis
(Table 3).
Potential adjuvant RT candidates
Figure 3 shows recurrence in remnant liver and/or
locoregional LNs of IHCC. Among 93 patients with re-
currence, 60 (64.5 %) recurred in remnant liver and/or
locoregional LNs and only 16 patients (17.2 %; gray area
in Fig. 4) were included in the hypothetical RT field.
Forty-four patients recurred in remnant liver more than
2 cm far from the cut surface with or without locoregio-
nal LN metastasis, in other words, recurred beyond the
RT field (white area in Fig. 4). Among the 16 patients,
two patients recurred in the liver, 12 recurred in locore-
gional LNs, and two patients recurred in both the liver
and locoregional LNs. Among patient recurred, tumor
size (p < 0.001) was the only predictive factor of recur-
rence beyond the hypothetical RT field. The optimal cut-
off point for tumor size as a predictor of recurrence
beyond the hypothetical RT field was ≥5.0 cm (p = 0.045
Fig. 3 Recurrence pattern of intrahepatic cholangiocarcinoma (n = 93)
Table 1 Clinicopathologic characteristics of patients with
intrahepatic cholangiocarcinoma (n = 153)





Wedge resection 3 (2.0)
Segmentectomy 11 (7.2)
Multiple segmentectomy 25 (16.3)
Hemihepatectomy 92 (60.1)
Extended hemihepatectomy 22 (14.4)
Pathologic characteristics
Tumor size, cm 4.5 (0.5–14.0)
Tumor size ≥4 cm 97 (63.4)
Multiple tumors 37 (24.2)
Lymphadenectomy performed 81 (52.9)
LN positive disease 38 (24.8)
Number of LN retrieved 7 (1–44)
Number of positive nodes 0 (0–22)
Subtype
Mass forming 117 (76.5)
Periductal infiltrative 36 (23.5)
Histology
Adenocarcinoma 140 (91.5 %)
Non-adenocarcinoma 13 (8.5 %)
Lymphovascular invasion 55 (35.9)
Perineural invasion 36 (23.5)
LN lymph node
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were no statistically significant factors between four pa-
tients recurred in remnant liver within 2 cm of COM
and other recurred patients.
Discussion
Surgical resection is the only potential cure for IHCC.
Although resectability of IHCC has improved recently
[10], the success rate remains poor [10, 11]. Even in pa-
tients who are able to undergo surgical resection, posi-
tive margins are common [10, 11]. The use of R0
resection provides the best chance for cure but is only
achievable in about 30 % of patients at presentation [11].
Studies have demonstrated that patients who had an
R1 resection had a survival similar to those who were
treated palliatively (5 vs. 7 months) and that local
recurrence is a major problem in patients with R1 re-
sections [11, 26].
Even after R0 resection, many studies reported recur-
rence rates more than 50 %, representing that resection
alone is not sufficient for most patients [1, 6–9, 12, 13].
Like other studies, our data shows 60.8 % recurrence
rate in IHCC after R0 resection. In patients with recur-
rence, palliative treatments such as radiation and sys-
temic chemotherapy could be considered. Earlier reports
of postoperative adjuvant therapy for the treatment of
biliary tract carcinoma have indicated the potential use-
fulness of radiotherapy and chemotherapy [27–30].
However, current studies testing the role of adjuvant
chemotherapy in IHCC are limited [14–16]. While adju-
vant radiation therapy may improve survival in patients
with microscopically positive margins, this remains con-
troversial [17–21]. Moreover, nearly all these studies
were based on cases of noncurative resection and were
experimental reports rather than clinical trial reports. In
addition, some hilar CC have been misclassified as
Table 2 Predictors of recurrence after resection of intrahepatic cholangiocarcinoma (n = 153)
Characteristic Univariate Multivariate
HR (95 % CI) p value HR (95 % CI) p value
Sex 1.046 (0.688–1.589) 0.835
Age 1.011 (0.988–1.034) 0.360
PT–INR 7.894 (1.041–59.841) 0.046
Type of resection 0.483
Wedge resection 0.917 (0.223–9.767) 0.904
Segmentectomy 1.264 (0.601–2.661) 0.537
Multiple segmentectomy 0.729 (0.399–1.335) 0.306
Hemihepatectomy 1
Extended hemihepatectomy 1.419 (0.799–2.518) 0.232
Tumor subtype 0.386 (0.221–0.676) 0.001
Histology 0.394 (0.144–1.075) 0.069
Tumor size ≥4.0 cm 2.932 (1.830–4.696) <0.001 2.522 (1.556–4.088) <0.001
Multiple tumors 2.020 (1.279–3.191) 0.003 1.815 (1.125–2.927) 0.015
LVI 1.866 (1.232–2.826) 0.003
PNI 1.825 (1.156–2.880) 0.010
LN metastasis 2.277 (1.424–3.642) 0.001 2.004 (1.221–3.289) 0.006
Resection margin 0.988 (0.972–1.044) 0.144
HBV 1.135 (0.685–1.881) 0.623
HCV 1.550 (0.624–3.849) 0.345
LVI lymphovascular invasion, PNI perineural invasion, HBV hepatitis B virus, HCV hepatitis C virus, PT–INR prothrombin time–international normalized ratio
Table 3 Predictors of survival after resection of intrahepatic cholangiocarcinoma (n = 153)
Characteristic Univariate Multivariate
HR (95 % CI) p value HR (95 % CI) p value
Sex 0.873 (0.568–1.344) 0.538
Age 1.011 (0.988–1.036) 0.347
PT–INR 24.618 (3.449–161.735) 0.001
Type of resection 0.137
Wedge resection 0.450 (0.062–3.258) 0.429
Segmentectomy 0.949 (0.432–2.087) 0.897
Multiple segmentectomy 0.655 (0.343–1.252) 0.201
Hemihepatectomy 1
Extended hemihepatectomy 1.677 (0.969–2.903) 0.065
Tumor subtype 0.367 (0.207–0.654) 0.001 0.536 (0.297–0.968) 0.039
Histology 0.680 (0.314–1.475) 0.329
Tumor size ≥4.0 cm 3.162 (1.928–5.184) <0.001 2.539 (1.512–4.264) <0.001
Multiple tumor 2.475 (1.585–3.864) <0.001 1.782 (1.122–2.828) 0.014
LVI 2.299 (1.520–3.475) <0.001 1.684 (1.107–2.564) 0.015
PNI 1.869 (1.181–2.957) 0.008
LN metastasis 3.902 (2.499–6.091) <0.001 3.567 (2.240–5.680) <0.001
Resection margin 0.991 (0.974–1.008) 0.294
HBV 1.165 (0.695–1.955) 0.562
HCV 1.226 (0.496–3.026) 0.659
LVI lymphovascular invasion, PNI perineural invasion, HBV hepatitis B virus, HCV hepatitis C virus, PT–INR prothrombin time–international normalized ratio
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Fig. 4 Recurrence in remnant liver and/or locoregional LNs of intrahepatic cholangiocarcinoma (n = 60). Patients in gray area (n = 16) included
hypothetical radiation therapy field
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of adjuvant therapy for carcinoma of the biliary tract has
not yet been clarified, and no guidelines for adjuvant
therapy for IHCC exist [22]. The benefit of postoperative
adjuvant RT will depend on appropriate patient selec-
tion. So, authors determined to identify a patient subset
at high risk for locoregional tumor recurrence after R0
resection and a subgroup among these patients who
could be covered within the RT field.
As mentioned above, some hilar CC have been mis-
classified as IHCC and many studies included R1 resec-
tion also. However, this report included only patients
with pathologically confirmed IHCC with R0 resection.
Patients with perihilar or distal CC, history of other ma-
lignancy, history of neoadjuvant therapy (TACE and
chemotherapy), M1 disease, and R1 and R2 diseases
were excluded from this analysis. After curativeTable 4 Predictors of recurrence beyond the radiation therapy
field in recurrent patients (n = 93)
Characteristic HR (95 % CI) p value
Sex 1.194 (0.745–1.914) 0.462
Age 0.976 (0.948–1.004) 0.095
PT–INR 7.155 (0.498–102.760) 0.148
Tumor subtype 0.566 (0.294–1.092) 0.090
Histology 0.753 (0.234–2.426) 0.635
Tumor size 1.204 (1.101–1.317) <0.001
Tumor size ≥5.0 cm 3.140 (1.890–5.217) <0.001
LVI 1.288 (0.810–2.049) 0.284
PNI 1.239 (0.745–2.060) 0.409
LN metastasis 1.567 (0.924–2.655) 0.095
Resection margin 0.985 (0.968–1.004) 0.113
HBV 0.806 (0.448–1.450) 0.471
HCV 1.236 (0.496–3.085) 0.649
LVI lymphovascular invasion, PNI perineural invasion, HBV hepatitis B virus, HCV
hepatitis C virus, PT–INR prothrombin time–international normalized ratioresection, two patients had adjuvant chemoradiation
therapy. A patient was 53 years old, female, and with
multiple IHCC. The maximum tumor size was 5.5 cm.
IHCC recurred after 15 months of surgery. Another pa-
tient was 48 years old, female, and with multiple IHCC.
The maximum tumor size was 7.8 cm, and LN metasta-
sis exists during surgery. IHCC recurred after a month,
and she died after 4 months of surgery. Because only
two patients had adjuvant treatment, it was impossible
to analyze statistical significance. And after IHCC recur-
rence, 12 patients had palliative chemoradiation therapy
and a patient had palliative RT. There was no significant
difference about survival between two groups that had
palliative treatment or not (data not shown).
Jarnagin et al. [31] reported about adjuvant treatment
after surgery of extrahepatic cholangiocarcinoma. After
surgery, locoregional recurrence is a predominant pat-
tern of failure even with R0 resection, and as local failure
can be associated with liver failure and death, this argues
for adjuvant radiation and chemoradiation therapy to
prevent local recurrence. Shinohara et al. [21] reported
radiation used adjuvantly with surgery was associated
with an improved median survival compared with radi-
ation alone and was associated with a 9.3 % reduction in
the risk of death. However, although radiation did pro-
long survival in these patients, it did not appear to cure
their disease. And these studies did not specify the cri-
teria about adjuvant treatment candidates after curative
resection. The benefit of adjuvant RT in resected IHCC
will depend on appropriate patient selection.
Pathologic factors that predict increased rates of recur-
rence and worse outcomes include multiple hepatic tu-
mors, nodal involvement, and vascular invasion, which
was reflected in the current American Joint Committee
on Cancer (AJCC) 7th edition staging system [8, 32]. Al-
though LN stats have been strongly associated with
prognosis in almost all studies [33–35], data on tumor
size have been more disparate, with some studies finding
Gil et al. World Journal of Surgical Oncology  (2015) 13:227 Page 8 of 9no effect of tumor size [36–38] and other larger studies
showing that size affected survival [33–35]. Previously,
the failure to identify an effect of tumor size on OS may
be explained by the limited number of patients with
small (e.g., <5 cm) tumors included in many prior stud-
ies. Our study found a tumor size larger than 4 cm is an
important risk factor of recurrence and survival. More-
over, tumor size larger than 5 cm is the only risk factor
of recurrence beyond the hypothetical RT field. Previous
studies did not consider about tumor size as an indica-
tion of adjuvant treatment. Future studies about adju-
vant RT and the AJCC staging system may need to
reconsider the impact of tumor size on prognosis and
should include tumor size as selection criteria of adju-
vant treatment.
Our findings should be interpreted in view of certain
limitations. First, retrospective study and the sample size
were small. Moreover, this study was accrued over a long
period (1995–2012), while both diagnostic and thera-
peutic procedures for IHCC have changed notably over
these years. There may be a selection bias in how pa-
tients were chosen for surgical therapy. Therefore, fur-
ther multicentric prospective and randomized clinical
trials are needed to determine the usefulness of adjuvant
RT to control locoregional recurrence after R0 resection.
With IHCC, NCCN recommendations include ob-
servation for R0 resection or some type of adjuvant
therapy for R1 or R2 resections. However, this study
demonstrates that tumor recurrence is common
(60.8 %) after complete resection (R0) of IHCC. In
this light, after R0 curative liver resection, observation
is not appropriate. For control of recurrence, aggres-
sive adjuvant treatment should be considered even if
curative resection is achieved. In our study, tumor
size ≥4.0 cm, LN metastasis, and multiple tumors pre-
dicted recurrence after curative resection. Among re-
curred patients, locoregional recurrence covered in
the hypothetical RT field occurred less than 20 %.
Even though a small portion of patients recurred in
hypothetical RT field, authors consider postoperative
RT might be a useful adjuvant modality because RT
could sterilize the field; as a result, it could lead to
lower the recurrence rate by lowering in and out field
recurrence rate.
The benefit of adjuvant therapy in resected IHCC will
depend on appropriate patient selection. Consequently,
for producing positive effect about adjuvant RT after R0
resection in IHCC, RT candidates should be carefully se-
lected in patients with recurrence factors, especially pa-
tients with a tumor size larger than 5 cm.
Conclusion
For cholangiocarcinomas, the tumor location and resect-
ability remain prime factors in disease control, whereasadjuvant chemotherapy and radiation remain more
controversial. However, surgical resection alone is not
sufficient for IHCC despite curative resection. We
suggest that patients with tumor size larger than
4 cm, LN metastasis, and multiple tumors could be
considered about receiving adjuvant RT for control of
locoregional recurrence after R0 resection. However,
patients with a tumor size larger than 5 cm should be
carefully selected as adjuvant RT candidates. Further
studies investigating the subset of high-risk recur-
rence groups as well as optimal adjuvant therapy for
IHCC are needed.
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